Intensity Therapeutics Secures 180-Day Nasdaq Compliance Extension
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 1 hour ago0mins
- Compliance Extension: Intensity Therapeutics has been granted a 180-day extension by Nasdaq, with a new deadline of June 1, 2026, to meet the minimum bid price requirement of $1.00 per share, thereby mitigating delisting risks.
- Market Reaction: Although the extension notification has no immediate effect on the trading of the company's shares, it is crucial for the company to maintain a closing bid price of at least $1.00 for ten consecutive business days during the extension period to ensure continued listing on Nasdaq.
- Monitoring Actions: The company intends to actively monitor its stock's closing bid price and take necessary actions to cure the deficiency, ensuring compliance before the deadline.
- Clinical Progress: Intensity is conducting multiple clinical trials, including a Phase 1/2 study for metastatic cancers and a Phase 2 randomized controlled trial for locally advanced breast cancer, demonstrating the potential of its therapeutic approach, which may influence future market performance.
INTS.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on INTS
Wall Street analysts forecast INTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTS is 3.33 USD with a low forecast of 1.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.410
Low
1.50
Averages
3.33
High
5.00
Current: 0.410
Low
1.50
Averages
3.33
High
5.00
Benchmark
Robert Wasserman
Speculative Buy
downgrade
$4
2025-08-20
Reason
Benchmark
Robert Wasserman
Price Target
$4
2025-08-20
downgrade
Speculative Buy
Reason
Benchmark analyst Robert Wasserman lowered the firm's price target on Intensity Therapeutics to $1.50 from $4 and keeps a Speculative Buy rating on the shares after the company reported Q2 results and provided an update on their clinical pipeline. The firm cites recent share dilution for its revised price target.
Brookline
Hold
to
Buy
upgrade
$3
2025-08-12
Reason
Brookline
Price Target
$3
2025-08-12
upgrade
Hold
to
Buy
Reason
Brookline upgraded Intensity Therapeutics to Buy from Hold with a $3 price target following Q2 results. Raising $11M extends the cash runway to the second half of 2026, notes the firm, which also cites the advancement of the Phase 2 triple negative breast cancer trial. The firm foresees "a favorable risk-reward as INT230-6 advances through the clinic," the analyst tells investors.
ThinkEquity
NULL -> Buy
initiated
$3
2025-07-28
Reason
ThinkEquity
Price Target
$3
2025-07-28
initiated
NULL -> Buy
Reason
ThinkEquity initiated coverage of Intensity Therapeutics with a Buy rating and $3 price target. The company has pivoted its clinical focus, creating a "high-risk, high-reward investment opportunity" centered around a near-term catalyst, the analyst tells investors in a research note. The sees a "compelling opportunity" into the Phase 2 INVINCIBLE-4 study evaluating Intensity's lead asset, INT230-6, in neoadjuvant triple-negative breast cancer.
Alliance Global Partners
Buy
downgrade
2025-05-22
Reason
Alliance Global Partners
Price Target
2025-05-22
downgrade
Buy
Reason
Alliance Global Partners lowered the firm's price target on Intensity Therapeutics to $3.50 from $8.50 and keeps a Buy rating on the shares. The price target reduction reflects the trial delay for INT230-6 for soft tissue sarcoma, the analyst tells investors in a research note. The trial is being paused until further notice due to funding constraints, and the firm believes it will take a major funding event to get it back on track.
See All Ratings
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the significance of the 180-day Nasdaq compliance extension?
How does the compliance extension impact Intensity Therapeutics' delisting risks?
Will Intensity Therapeutics meet the $1.00 bid price requirement by June 2026?
How might the compliance extension influence Intensity Therapeutics' stock performance?